Key regions: Australia, Japan, United States, Germany, Europe
The Anti-Coagulants market in Turkey has been experiencing significant growth in recent years.
Customer preferences: One of the key drivers of this growth is the increasing prevalence of cardiovascular diseases in Turkey. As a result, there is a growing demand for Anti-Coagulants drugs, which are used to prevent blood clots that can lead to heart attacks and strokes. In addition, there is a growing awareness among Turkish consumers about the importance of preventive healthcare, which is also contributing to the growth of the Anti-Coagulants market.
Trends in the market: One of the major trends in the Anti-Coagulants market in Turkey is the increasing use of novel oral anticoagulants (NOACs), which are newer and more effective than traditional anticoagulants such as warfarin. This trend is driven by the fact that NOACs have fewer side effects and do not require frequent blood tests, which makes them more convenient for patients.Another trend in the market is the increasing use of combination therapy, which involves the use of two or more anticoagulants to achieve better outcomes. This trend is driven by the fact that many patients with cardiovascular diseases have multiple risk factors, and a combination of drugs can help to address these risk factors more effectively.
Local special circumstances: One of the key factors that is driving the growth of the Anti-Coagulants market in Turkey is the country's aging population. As people age, they are more likely to develop cardiovascular diseases, which increases the demand for Anti-Coagulants drugs. In addition, the Turkish government has been investing heavily in healthcare infrastructure in recent years, which has improved access to healthcare services for the population.
Underlying macroeconomic factors: The Turkish economy has been growing steadily in recent years, which has led to an increase in disposable income among Turkish consumers. This has contributed to the growth of the Anti-Coagulants market, as consumers are more willing and able to pay for healthcare services. In addition, Turkey has a large and growing pharmaceutical industry, which has helped to drive innovation and competition in the Anti-Coagulants market. Overall, the Anti-Coagulants market in Turkey is expected to continue to grow in the coming years, driven by these underlying macroeconomic factors and the increasing prevalence of cardiovascular diseases in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
